PriceTargets.com logo

Jade Biosciences - JBIO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $47.13
  • Forecasted Upside: 186.95%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$16.42 As of 06/17/2026 02:56 PM ET
▲ +0.893 (5.75%)

This chart shows the closing price for JBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jade Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JBIO

Analyst Price Target is $47.13
▲ +186.95% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Jade Biosciences in the last 3 months. The average price target is $47.13, with a high forecast of $74.00 and a low forecast of $16.00. The average price target represents a 186.95% upside from the last price of $16.42.

This chart shows the closing price for JBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Jade Biosciences. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
3/19/2026
  • 2 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2026
  • 3 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/15/2026UBS GroupInitiated CoverageBuy$45.00
6/15/2026UBS GroupInitiated CoverageBuy$45.00
6/2/2026Piper SandlerSet Target$55.00
6/2/2026GuggenheimReiterated RatingBuy ➝ Buy$47.00
6/2/2026WedbushBoost TargetOutperform ➝ Outperform$34.00 ➝ $45.00
6/1/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy
6/1/2026Weiss RatingsUpgradeSell (D-) ➝ Sell (D)
6/1/2026BTIG ResearchBoost TargetBuy ➝ Buy$39.00 ➝ $74.00
6/1/2026HC WainwrightBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
5/27/2026BTIG ResearchReiterated RatingBuy ➝ Buy$39.00
5/11/2026Weiss RatingsDowngradeSell (D) ➝ Sell (D-)
5/11/2026GuggenheimBoost TargetBuy ➝ Buy$23.00 ➝ $32.00
5/11/2026WedbushBoost TargetOutperform ➝ Outperform$24.00 ➝ $34.00
4/27/2026HC WainwrightBoost TargetBuy ➝ Buy$35.00 ➝ $45.00
4/24/2026Weiss RatingsUpgradeSell (D-) ➝ Sell (D)
4/10/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/8/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
3/25/2026HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $35.00
3/16/2026BTIG ResearchBoost TargetBuy ➝ Buy$28.00 ➝ $39.00
3/11/2026GuggenheimBoost TargetBuy ➝ Buy$17.00 ➝ $23.00
3/10/2026Zacks ResearchDowngradeHold ➝ Strong Sell
3/9/2026William BlairUpgradeStrong-Buy
3/9/2026WedbushReiterated RatingOutperform ➝ Outperform$24.00
3/6/2026Stifel NicolausSet Target$40.00
3/6/2026Lifesci CapitalUpgradeStrong-Buy
1/7/2026HC WainwrightInitiated CoverageBuy$25.00
1/7/2026HC WainwrightInitiated CoverageBuy$25.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/18/2025GuggenheimBoost TargetBuy ➝ Buy$14.00 ➝ $17.00
10/31/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
10/9/2025BTIG ResearchInitiated CoverageBuy$28.00
10/9/2025BTIG ResearchInitiated CoverageBuy$28.00
10/8/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
9/27/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
8/14/2025WedbushBoost TargetOutperform ➝ Outperform$17.00 ➝ $18.00
7/14/2025Jefferies Financial GroupInitiated CoverageBuy$16.00
6/16/2025GuggenheimUpgradeNeutral ➝ Buy$14.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 9 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 9 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Jade Biosciences logo
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $16.42
Low: $15.27
High: $16.52

50 Day Range

MA: $21.00
Low: $14.98
High: $26.85

52 Week Range

Now: $16.42
Low: $6.67
High: $28.00

Volume

250,723 shs

Average Volume

583,899 shs

Market Capitalization

$810.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Jade Biosciences?

The following equities research analysts have issued research reports on Jade Biosciences in the last twelve months: BTIG Research, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Piper Sandler, Stifel Nicolaus, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for JBIO.

What is the current price target for Jade Biosciences?

0 Wall Street analysts have set twelve-month price targets for Jade Biosciences in the last year. Their average twelve-month price target is $47.13, suggesting a possible upside of 203.4%. BTIG Research has the highest price target set, predicting JBIO will reach $74.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $16.00 for Jade Biosciences in the next year.
View the latest price targets for JBIO.

What is the current consensus analyst rating for Jade Biosciences?

Jade Biosciences currently has 1 sell rating, 1 hold rating, 5 buy ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JBIO will outperform the market and that investors should add to their positions of Jade Biosciences.
View the latest ratings for JBIO.

What other companies compete with Jade Biosciences?

Other companies that are similar to Jade Biosciences include Structure Therapeutics, Arcutis Biotherapeutics, Beam Therapeutics, Adaptive Biotechnologies and Dyne Therapeutics. Learn More about companies similar to Jade Biosciences.

How do I contact Jade Biosciences' investor relations team?

Jade Biosciences' physical mailing address is 930 WINTER STREET, SUITE M-500, WALTHAM, MA, 02451. The company's listed phone number is (617) 443-2400 and its investor relations email address is [email protected]. The official website for Jade Biosciences is aerovatetx.com. Learn More about contacing Jade Biosciences investor relations.